These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33429726)

  • 1. Bisphosphonates and risk of lung cancer: Protocol for a systematic review and meta-analysis.
    Li M; Zhong M; Guan C
    Medicine (Baltimore); 2021 Jan; 100(1):e22839. PubMed ID: 33429726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis.
    Wright E; Schofield PT; Molokhia M
    BMJ Open; 2015 Dec; 5(12):e007133. PubMed ID: 26644118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates use and risk of gastric cancer: an updated meta-analysis of cohort and case-control studies.
    Cai D; Qin J; Chen G; Feng W; Liu J
    Minerva Med; 2017 Oct; 108(5):464-472. PubMed ID: 28466630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis.
    Lee SH; Chang SS; Lee M; Chan RC; Lee CC
    Osteoporos Int; 2014 Mar; 25(3):1131-9. PubMed ID: 24343364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis.
    Loke YK; Jeevanantham V; Singh S
    Drug Saf; 2009; 32(3):219-28. PubMed ID: 19338379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer.
    Andrici J; Tio M; Eslick GD
    Aliment Pharmacol Ther; 2012 Oct; 36(8):708-16. PubMed ID: 22966908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies.
    Sun K; Liu JM; Sun HX; Lu N; Ning G
    Osteoporos Int; 2013 Jan; 24(1):279-86. PubMed ID: 23052941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential risks of rare serious adverse effects related to long-term use of bisphosphonates: An overview of systematic reviews.
    Lu L; Lu L; Zhang J; Li J
    J Clin Pharm Ther; 2020 Feb; 45(1):45-51. PubMed ID: 31608489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates and risk of cardiovascular events: a meta-analysis.
    Kim DH; Rogers JR; Fulchino LA; Kim CA; Solomon DH; Kim SC
    PLoS One; 2015; 10(4):e0122646. PubMed ID: 25884398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can Bisphosphonates Prevent Recurrent Fragility Fractures? A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Lee SY; Jung SH; Lee SU; Ha YC; Lim JY
    J Am Med Dir Assoc; 2018 May; 19(5):384-390.e1. PubMed ID: 29704927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral bisphosphonates and the risk of colorectal cancer: a meta-analysis.
    Yang G; Hu H; Zeng R; Huang J
    J Clin Gastroenterol; 2013 Oct; 47(9):741-8. PubMed ID: 24030705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials.
    Li YT; Cai HF; Zhang ZL
    Osteoporos Int; 2015 Feb; 26(2):431-41. PubMed ID: 25266485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Citrus fruit intake and lung cancer risk: A meta-analysis of observational studies.
    Wang J; Gao J; Xu HL; Qian Y; Xie L; Yu H; Qian BY
    Pharmacol Res; 2021 Apr; 166():105430. PubMed ID: 33529754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates for Paget's disease of bone in adults.
    Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis.
    Serrano AJ; Begoña L; Anitua E; Cobos R; Orive G
    Gynecol Endocrinol; 2013 Dec; 29(12):1005-14. PubMed ID: 24063695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Treatment With Bisphosphonates of Osteoporosis Does Not Increase the Risk of Severe Gastrointestinal Side Effects: A Meta-Analysis of Randomized Controlled Trials.
    Dömötör ZR; Vörhendi N; Hanák L; Hegyi P; Kiss S; Csiki E; Szakó L; Párniczky A; Erőss B
    Front Endocrinol (Lausanne); 2020; 11():573976. PubMed ID: 33240217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Systematic Review and Meta-Analysis about the Effect of Bisphosphonates on the Risk of Skeletal-Related Event in Men with Prostate Cancer.
    Wu C; Jiang H; Chen J
    Anticancer Agents Med Chem; 2020; 20(13):1604-1612. PubMed ID: 32436834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
    Nayak S; Greenspan SL
    Osteoporos Int; 2019 Apr; 30(4):705-720. PubMed ID: 30623214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral bisphosphonates and incidence of cancers in patients with osteoporosis: a systematic review and meta-analysis.
    Deng Y; Zhang Z; Jia X; Cheng W; Zhou X; Liu Y; Wang M
    Arch Osteoporos; 2018 Dec; 14(1):1. PubMed ID: 30560459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.